Skip to main content
    I

    Insmed Inc (INSM)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $122.88
    +1.72 (+1.42%)

    Market Cap: $26.58B

    Last updated: Nov 17, 2026 at 11:06 AM ET

    Insmed Inc (INSM) Stock Forecast

    Updated Nov 17, 2026. Estimates and ratings come from consensus analyst data.

    Analysts expect Insmed (INSM) to earn -$1.67 per share in the fiscal year ending Dec 31, 2026, on revenue of $1.86B. Of 24 analysts, 23 rate the stock Buy or Strong Buy, 1 Hold and 0 Sell or Strong Sell, for a consensus of Buy. Over the last 30 days, 3 estimates for the fiscal year ending Dec 31, 2026 were revised up and 5 down.

    Analyst Ratings

    Scoring Strong Buy as 1 and Strong Sell as 5, the 24 ratings average 1.83, inside the Buy band from 1.5 up to 2.5. Buy and Strong Buy make up 96% of the ratings.

    RatingAnalystsShare
    Strong Buy520.8%
    Buy1875.0%
    Hold14.2%
    Sell00.0%
    Strong Sell00.0%
    Consensus
    Buy
    Total analysts
    24

    Price Target

    Analyst price targets are part of paid GNG plans. See plans

    Annual Estimates

    From the first fiscal year below to the second, the EPS consensus turns from a loss to a profit and revenue estimates rise 60.8%.

    Fiscal year ending Dec 31, 2026
    -$1.67
    EPS consensus, revenue $1.86B
    Fiscal year ending Dec 31, 2027
    $0.66
    EPS consensus, revenue $2.99B
    Next report
    Feb 17, 2027
    Estimated

    EPS range

    Revenue range

    Fiscal year endingEPS consensusEPS rangeEPS analystsRevenue consensusRevenue rangeRev. analysts
    Dec 31, 2026-$1.67-$2.17 to -$0.8217$1.86B$1.84B to $1.89B20
    Dec 31, 2027$0.66-$0.82 to $2.0218$2.99B$2.58B to $3.38B21

    Quarterly Estimates

    The EPS consensus rises from -$0.33 for the quarter ending Dec 31, 2026 to -$0.28 for the quarter ending Mar 31, 2027.

    EPS range

    Revenue range

    Quarter endingEPS consensusEPS rangeEPS analystsRevenue consensusRevenue rangeRev. analysts
    Dec 31, 2026-$0.33-$1.12 to -$0.0225$604.78M$530.18M to $664.88M23
    Mar 31, 2027-$0.28-$0.53 to -$0.066$625.63M$555.00M to $666.18M9

    Estimate Revisions

    Across the 2 periods below, the last 30 days brought 9 upward and 13 downward EPS revisions. Cuts outnumber raises in every period.

    PeriodUp 30 daysDown 30 days
    Fiscal year ending Dec 31, 202635
    Fiscal year ending Dec 31, 202768

    EPS Trend

    Over the last 90 days, the EPS consensus for the fiscal year ending Dec 31, 2026 has improved from -$2.63.

    PeriodNow7 days ago30 days ago60 days ago90 days agoChange
    Fiscal year ending Dec 31, 2026-$1.67-$1.59-$1.54-$1.55-$2.63N/A
    Fiscal year ending Dec 31, 2027$0.66$0.79$0.77$0.80$0.12+427.3%
    Quarter ending Mar 31, 2027-$0.28-$0.23-$0.20-$0.20-$0.22N/A

    Frequently Asked Questions About INSM

    What is the INSM stock forecast?

    Consensus analyst estimates put Insmed's EPS at -$1.67 for the fiscal year ending Dec 31, 2026, on revenue of $1.86B. The consensus rating from 24 analysts is Buy.

    How do analysts rate INSM stock?

    Of 24 analysts covering Insmed, 5 rate it Strong Buy, 18 Buy, 1 Hold, 0 Sell and 0 Strong Sell, for a consensus of Buy.

    What EPS do analysts expect from INSM next year?

    For the fiscal year ending Dec 31, 2026, the consensus EPS estimate is -$1.67, with estimates from -$2.17 to -$0.82 from 17 analysts. For the fiscal year ending Dec 31, 2027, the consensus EPS estimate is $0.66, with estimates from -$0.82 to $2.02 from 18 analysts.

    What revenue do analysts expect from Insmed next year?

    For the fiscal year ending Dec 31, 2026, the consensus revenue estimate is $1.86B, with estimates from $1.84B to $1.89B. For the fiscal year ending Dec 31, 2027, the consensus revenue estimate is $2.99B, with estimates from $2.58B to $3.38B.

    How many analysts cover INSM?

    24 analysts rate Insmed stock, and 17 analysts estimate its EPS for the fiscal year ending Dec 31, 2026.